Lanier Biotherapeutics Announces Issuance of U.S. Patent for IL-25 Binding Molecules
This patent covers our novel approach to treating Type 2 inflammatory disease and is a key addition to our growing intellectual property estate, said Daniel White, President and CEO of Lanier.
- This patent covers our novel approach to treating Type 2 inflammatory disease and is a key addition to our growing intellectual property estate, said Daniel White, President and CEO of Lanier.
- Because many currently available treatments for Type 2 inflammatory disease target particular downstream cytokines, they miss the opportunity to target other mediators.
- IL-25 binding molecules, including LNR 125, target upstream cytokines called the Alarmins, the very first inflammatory trigger, which enables an effect on all downstream cytokines simultaneously.
- Lanier Biotherapeutics was founded to develop first-in-class biologics portfolio for specialty disease, with the ultimate goal of improving the way we survive, age, and live.